Helix BioPharma Corp. saw a modest increase in stock price amid a challenging year.
This week, Helix BioPharma Corp. (HBP.TO) closed at C$1.40, reflecting a 2.14% gain for the day. However, the stock has declined by 0.69% over the past week and is down 40.42% year-to-date. Despite the recent uptick, the overall performance in 2023 suggests ongoing challenges for the company.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Helix BioPharma Corp.
HBP.TO
HBP.TO
Helix BioPharma Corp.
WealthAwesomeMarket cap
$106.93M
52W high
$5.40
52W low
$0.95
1W change
-0.69%
Beta
-0.35
Analyst Price Targets
Based on analyst covering HBP
Wall Street analysts forecast HBP stock price to rise 74.8% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.50
+74.8% Upside
Current Price
C$1.43
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HBP's historical volatility
30-Day Vol
53.5%
Annualized
90-Day Vol
69.9%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$1.20
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$1.35 | C$1.12 โ C$1.62 |
| 60 trading days | C$1.27 | C$0.98 โ C$1.65 |
| 90 trading days | C$1.20 | C$0.87 โ C$1.65 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors in Helix BioPharma Corp. should consider the stock's recent performance and the broader market context, especially as the company navigates its financial landscape and strategic initiatives.
Helix BioPharma Corp. Sees 40.42% Decline YTD
With a market cap of C$106.93 million and a beta of -0.35, Helix BioPharma's stock has shown lower volatility compared to the broader market, reflecting its niche position in the healthcare sector.
Bull case
Analysts are optimistic about Helix BioPharma, with an average price target of C$2.50, indicating significant upside potential. The company's efforts to secure financing for its therapeutic programs may also support future growth.
Bear case
Despite the potential for growth, Helix BioPharma's negative profit margin and return on equity raise concerns about its financial health. Additionally, the stock's significant decline this year may deter risk-averse investors.
Recent Price Action
Helix BioPharma Corp. (HBP.TO) experienced a 2.14% increase today, closing at C$1.40. Over the past week, the stock has declined by 0.69%, and it remains significantly lower compared to its year-to-date performance, which shows a drop of 40.42%. Despite the recent gain, the stock continues to reflect the challenges faced by the company in a competitive healthcare sector.
Catalysts and Company News
There were no major company news announcements this week that might have influenced the stock price. However, Helix BioPharma has previously reported on its financial results and interim statements for the three- and nine-month periods ending April 30, 2026. Investors can find these details on the company's profile at SEDAR Plus and on their official website.
Technical Picture
From a technical standpoint, Helix BioPharma's stock is currently trading below its 50-day moving average of C$1.52, representing a 7.6% discount. The 200-day moving average stands at C$2.00, indicating a 30% decline from the current price. The stock's 52-week range is between C$0.95 and C$5.40, with the current price being approximately 10% of that range. The recent trading volume of 2,340 shares is slightly above the 20-day average of 1,208 shares, suggesting moderate interest among investors.
Insider Activity
There are no recent insider activity reports available for Helix BioPharma Corp.
Price Action Summary
As of the last close, Helix BioPharma Corp. (HBP.TO) stands at C$1.40, reflecting a 2.14% increase for the day. Investors should remain cautious, considering the stock's overall performance and market conditions.
Advertisement
